Thompson Davis & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

Thompson Davis & Co’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-127	Closed	-$11K	–	1151
2016 Q4	$11K	Buy	127 +28	+28%	+$2.41K	0.02%	666
2016 Q3	$9K	Buy	+99	New	+$9.32K	0.02%	681
2015 Q3	–	Sell	-200	Closed	-$27K	–	1137
2015 Q2	$27K	Buy	+200	New	+$24.8K	0.03%	455

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Thompson Davis & Co's BMRN Position: Q1 2017 in Review

Thompson Davis & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2017, closing a stake of 127 shares — an estimated $11K sold.

Thompson Davis & Co first reported a position in BMRN in Q2 2015 and held it in 3 quarters. The position peaked at $27K in Q2 2015. 417 funds tracked by Wall St. Rank hold BMRN as of Q1 2017.

Thompson Davis & Co reported no remaining BioMarin Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Thompson Davis & Co sold 127 BioMarin Pharmaceuticals shares in Q1 2017, an estimated $11K.
Thompson Davis & Co first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 3 quarters.
Thompson Davis & Co's BioMarin Pharmaceuticals position peaked at $27K in Q2 2015.
417 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2017.

Based on Thompson Davis & Co's 13F filing for Q1 2017, filed 8 May 2017.